Compared with primary tumors, the inhibitory effect of ASC in metastatic melanoma was gradually converted into a tumorigenic role through the improvement of NF-κB pathways and the secretion of inflammasome-medicated IL-1β43. Here, PYCARD is linked to metastatic melanoma.